JP2015519345A - 非天然コンセンサスアルブミン結合ドメイン - Google Patents

非天然コンセンサスアルブミン結合ドメイン Download PDF

Info

Publication number
JP2015519345A
JP2015519345A JP2015514183A JP2015514183A JP2015519345A JP 2015519345 A JP2015519345 A JP 2015519345A JP 2015514183 A JP2015514183 A JP 2015514183A JP 2015514183 A JP2015514183 A JP 2015514183A JP 2015519345 A JP2015519345 A JP 2015519345A
Authority
JP
Japan
Prior art keywords
binding domain
albumin binding
seq
isolated
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015514183A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイコブス，スティーブン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2015519345A publication Critical patent/JP2015519345A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015514183A 2012-05-25 2013-05-23 非天然コンセンサスアルブミン結合ドメイン Withdrawn JP2015519345A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US61/651,642 2012-05-25
US201361776918P 2013-03-12 2013-03-12
US61/776,918 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018115294A Division JP7166081B2 (ja) 2012-05-25 2018-06-18 非天然コンセンサスアルブミン結合ドメイン

Publications (1)

Publication Number Publication Date
JP2015519345A true JP2015519345A (ja) 2015-07-09

Family

ID=49622071

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015514183A Withdrawn JP2015519345A (ja) 2012-05-25 2013-05-23 非天然コンセンサスアルブミン結合ドメイン
JP2018115294A Active JP7166081B2 (ja) 2012-05-25 2018-06-18 非天然コンセンサスアルブミン結合ドメイン
JP2020158256A Pending JP2021019595A (ja) 2012-05-25 2020-09-23 非天然コンセンサスアルブミン結合ドメイン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018115294A Active JP7166081B2 (ja) 2012-05-25 2018-06-18 非天然コンセンサスアルブミン結合ドメイン
JP2020158256A Pending JP2021019595A (ja) 2012-05-25 2020-09-23 非天然コンセンサスアルブミン結合ドメイン

Country Status (15)

Country Link
US (3) US9156887B2 (enExample)
EP (1) EP2855509B1 (enExample)
JP (3) JP2015519345A (enExample)
KR (1) KR102053674B1 (enExample)
CN (1) CN104470944B (enExample)
AU (2) AU2013266215B2 (enExample)
BR (1) BR112014029409B1 (enExample)
CA (1) CA2874646C (enExample)
DK (1) DK2855509T3 (enExample)
EA (1) EA036487B1 (enExample)
ES (1) ES2670442T3 (enExample)
IL (2) IL235808A (enExample)
MX (1) MX355041B (enExample)
PT (1) PT2855509T (enExample)
WO (1) WO2013177398A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506693A (ja) * 2017-01-24 2020-03-05 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP2971290A4 (en) * 2013-03-14 2017-03-01 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
CA2979973A1 (en) * 2015-04-29 2016-11-03 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016204884A1 (en) * 2015-06-18 2016-12-22 Albert Einstein College Of Medicine, Inc. Fgf receptor ligands for treating diabetes and obesity
WO2017081082A2 (en) * 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
CN109153711B (zh) 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
JP7104703B2 (ja) 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
CN111050784B (zh) 2017-08-11 2024-03-19 伊利诺伊大学理事会 截短的豚鼠l-天冬酰胺酶变体及其使用方法
JP7545894B2 (ja) 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021127353A1 (en) * 2019-12-18 2021-06-24 Aro Biotherapeutics Company Serum albumin-binding fibronectin type iii domains and uses thereof
WO2021174107A2 (en) 2020-02-26 2021-09-02 Northwestern University Soluble ace2 variants and uses therefor
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
EP4615859A2 (en) * 2022-11-09 2025-09-17 Repligen Corporation Affinity agents
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011137319A2 (en) * 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
WO1993022439A1 (en) * 1992-05-07 1993-11-11 Microbiological Research Authority Immunoglobulin binding proteins derived from l protein and their uses
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
DE69841578D1 (de) 1997-09-16 2010-05-06 Centocor Inc Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
CN102307896B (zh) * 2008-10-31 2016-10-12 森托科尔奥索生物科技公司 基于iii型纤连蛋白结构域的支架组合物、方法及用途
EP2397547A4 (en) * 2009-02-10 2012-09-05 Univ Ryukyus DRUG CARRIER AND ADJUVANT AND VACCINE USING EACH
CA2752211C (en) 2009-02-12 2020-03-24 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
KR101958753B1 (ko) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 ｃｄ27에 결합하는 항체 및 이의 용도
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011137319A2 (en) * 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
DAI, M. ET AL., PROTEIN ENG. DES. SEL., vol. 20, no. 2, JPN7017000195, 2007, pages 69 - 79, ISSN: 0003485335 *
FORRER, P. ET AL., CHEMBIOCHEM, vol. 5, JPN6017001892, 2004, pages 183 - 189, ISSN: 0003701847 *
HE, Y. ET AL., BIOCHEMISTRY, vol. 45, JPN6017001891, 2006, pages 10102 - 10109, ISSN: 0003485334 *
JACOBS, S.A. ET AL., PROTEIN ENG. DES. SEL., vol. 25, no. 3, JPN6017001890, 12 January 2012 (2012-01-12), pages 107 - 117, ISSN: 0003485332 *
JOHANSSON, M.U. ET AL, J. MOL. BIOL., vol. 316, JPN6017047965, 2002, pages 1083 - 1099, ISSN: 0003701851 *
JOHANSSON, M.U. ET AL., J. MOL. BIOL., vol. 266, JPN6017047963, 1997, pages 859 - 865, ISSN: 0003701850 *
JONSSON, A. ET AL., PROTEIN ENG. DES. SEL., vol. 21, no. 8, JPN7017000194, 2008, pages 515 - 527, ISSN: 0003485333 *
LEHMANN, M. AND WYSS, M., CURR. OPIN. BIOTECHNOL., vol. 12, JPN6017001893, 2001, pages 371 - 375, ISSN: 0003485337 *
LEHMANN, M. ET AL., PROTEIN ENG., vol. 13, no. 1, JPN7017000196, 2000, pages 49 - 57, ISSN: 0003485338 *
LEJON, S. ET AL., J. BIOL. CHEM., vol. 279, JPN6017047968, 2004, pages 42924 - 42928, ISSN: 0003701852 *
LINHULT, M. ET AL., PROTEIN SCI., vol. 11, JPN6017047962, 2002, pages 206 - 213, ISSN: 0003701849 *
MAIN, E.R.G. ET AL., STRUCTURE, vol. 11, JPN6017047969, 2003, pages 497 - 508, ISSN: 0003701853 *
STEIPE, B., METHODS ENZYMOL., vol. 388, JPN6017001894, 2004, pages 176 - 186, ISSN: 0003701848 *
STUMPP, M.T. ET AL., J. MOL. BIOL., vol. 332, JPN6017047972, 2003, pages 471 - 487, ISSN: 0003701854 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506693A (ja) * 2017-01-24 2020-03-05 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
JP7332157B2 (ja) 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体

Also Published As

Publication number Publication date
JP2021019595A (ja) 2021-02-18
EP2855509A4 (en) 2016-01-13
AU2013266215A1 (en) 2014-12-04
EA036487B1 (ru) 2020-11-16
IL254652A0 (en) 2017-11-30
CA2874646C (en) 2020-12-01
KR102053674B1 (ko) 2019-12-09
US10280200B2 (en) 2019-05-07
MX2014014384A (es) 2015-05-11
BR112014029409B1 (pt) 2022-11-29
US20130316952A1 (en) 2013-11-28
BR112014029409A2 (enExample) 2017-08-15
IL235808A (en) 2017-10-31
DK2855509T3 (en) 2018-07-23
EP2855509B1 (en) 2018-05-02
CN104470944A (zh) 2015-03-25
KR20150016585A (ko) 2015-02-12
AU2013266215B2 (en) 2017-12-07
CA2874646A1 (en) 2013-11-28
EA201590136A1 (ru) 2016-02-29
CN104470944B (zh) 2021-09-14
JP7166081B2 (ja) 2022-11-07
WO2013177398A3 (en) 2014-03-27
PT2855509T (pt) 2018-08-03
US20180009854A1 (en) 2018-01-11
US9156887B2 (en) 2015-10-13
US20160083436A1 (en) 2016-03-24
AU2017261625A1 (en) 2017-12-07
ES2670442T3 (es) 2018-05-30
HK1209134A1 (en) 2016-03-24
EP2855509A2 (en) 2015-04-08
JP2018171063A (ja) 2018-11-08
WO2013177398A2 (en) 2013-11-28
MX355041B (es) 2018-03-28
IL254652B (en) 2019-12-31
IL235808A0 (en) 2015-01-29
AU2017261625B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
JP7166081B2 (ja) 非天然コンセンサスアルブミン結合ドメイン
US9260496B2 (en) Fibronectin based scaffold domain proteins that bind IL-23
CN102781960B (zh) Hsa相关组合物及使用方法
TWI508736B (zh) 結合至ｉｌ－２３之以纖維連接蛋白為主之架構域蛋白質
KR102461666B1 (ko) 혈청 알부민 결합 피브로넥틴 iii 형 도메인
CN105477641A (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
CN110950967B (zh) 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
HK1209134B (en) Non-natural consensus albumin binding domains
EA045108B1 (ru) Выделенный искусственный альбумин-связывающий домен и содержащий его слитый белок
JP6525171B2 (ja) 環状化サイトカイン及びその製法
CN117858982A (zh) 人纤连蛋白iii型蛋白支架
WO2021195177A1 (en) Qty fc fusion water soluble receptor proteins

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180828

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180913